This site is intended for a global audience

Contact Us

Home | About Jazz > History

History

History

U.S. FDA approval of Modeyso^TM

Acquired Chimerix in 2Q25

2025

2024

Acquired global rights to Redx Pharma's KRAS Inhibitor Program

U.S. FDA approval of Ziihera

20^th Anniversary of Jazz Pharmaceuticals founding

Jazz expands support for American Heart Association

2023

2022

Entered exclusive licensing agreement with Zymeworks Inc. for the HER2-targeted bispecific antibody, zanidatamab

Acquired global development and commercial rights for IFNα molecule from Werewolf Therapeutics, Inc. (JZP898)

Acquired development and commercial rights for Orexin-2receptor agonist from Sumitomo Pharma Co., Ltd. (JZP441)

FDA approval of Xywav for an additional patient population

Canada Launch of Vyxeos^®

U.S. Launch of Rylaze^®

Acquired GW Pharmaceuticals in 2Q21

FDA approval of Vyxeos for an additional patient population

2021

2020

European rolling launch of Sunosi^®

U.S. launch of Zepzelca™

Xywav™ U.S. approval

Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies

Acquired worldwide rights to SpringWorks Therapeutics’ FAAH Inhibitor Program

Acquired pre-clinical Pan-RAF inhibitor program from Redx Pharma

U.S. Launch of Sunosi^®

Entered into strategic collaboration with Codiak BioSciences

Acquired Cavion, including worldwide rights to JZP-385

Acquired rights to lurbinectedin in the U.S. from PharmaMar

2019

2018

FDA approval of Xyrem for an additional patient population

European rolling launch of Vyxeos^®

Entered into strategic collaboration with MD Anderson

Entered into strategic collaboration with ImmunoGen

U.S. Launch of Vyxeos^®

2017

2016

Opened new manufacturing facility in Athlone, Ireland and received a Facility of the Year Award in 2017 from the International Society for Pharmaceutical Engineering (ISPE) for Best Project Execution

Acquired Celator Pharmaceuticals, which added Vyxeos^®

U.S. launch of Defitelio^®

Initiation of JZP-110 Phase 3 clinical program

2015

2014

Acquired rights to defibrotide in the Americas from Sigma-Tau Pharma

Acquired Gentium, which added Defitelio^® (defibrotide) to our product portfolio; European commercial launch of Defitelio

Acquired rights to JZP-110 from Aerial BioPharma

Acquired EUSA Pharma, which extended our product offerings to include Erwinaze^®/ Erwinase^®, and helped us establish our European commercial infrastructure

Merger with Azur Pharma, which provided a new global headquarters in Dublin, Ireland, bringing in new employees and new members of our management team

2012

2005

Acquired Orphan Medical and its product, Xyrem^®

Management team assembled/capital raised

2004

2003

Jazz Pharmaceuticals founded